What was Alar Pharmaceuticals Inc’s price range in the past 12 months?
Alar Pharmaceuticals Inc lowest stock price was TWD 71.10 and its highest was TWD 317.00 in the past 12 months.
What is Alar Pharmaceuticals Inc’s market cap?
Alar Pharmaceuticals Inc’s market cap is TWD 4.93B.
When is Alar Pharmaceuticals Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Alar Pharmaceuticals Inc’s earnings last quarter?
Alar Pharmaceuticals Inc released its earnings results on Aug 06, 2026. The company reported TWD 0.233 earnings per share for the quarter.
Is Alar Pharmaceuticals Inc overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Alar Pharmaceuticals Inc pay dividends?
Alar Pharmaceuticals Inc pays a ― dividend of TWD 0.1 which represents an annual dividend yield of 0.14%. See more information on Alar Pharmaceuticals Inc dividends here
What is Alar Pharmaceuticals Inc’s EPS estimate?
Alar Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alar Pharmaceuticals Inc have?
Alar Pharmaceuticals Inc has 66,800,000 shares outstanding.
What happened to Alar Pharmaceuticals Inc’s price movement after its last earnings report?
Alar Pharmaceuticals Inc reported an EPS of TWD 0.233 in its last earnings report. Following the earnings report the stock price went down -4.825%.
Which hedge fund is a major shareholder of Alar Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in TW:6785
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alar Pharmaceuticals Inc
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson’s disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.